Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

OP is considering adding topical bimatoprost or latanoprost to their hair loss treatment, which already includes oral minoxidil, and is seeking reliable sources for these products. Users discuss the effectiveness and sourcing of these treatments, with some using bimatoprost for both hairline and eyelashes, and others planning to use latanoprost mixed with finasteride.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.

The conversation discusses difficulty in distinguishing between new hair growth and thinning hair at the temples after using microneedling and a rosemary peppermint topical for four weeks. The advice given is to wait a few months to see if the hairs grow out to determine their nature.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The conversation is about someone using topical dutasteride and oral minoxidil for hair loss, and they are seeking opinions on potential hair regrowth shown in a photo. Respondents agree that there is some progress.

The user believes Retrograde Alopecia may be linked to vitamin imbalances, specifically from taking too much Vitamin E, A, Zinc, and Selenium, and suggests it could be a middle ground between Androgenic Alopecia and Telogen Effluvium. Treatments for hair loss mentioned include Androgen inhibitors and improving lifestyle factors like nutrition and sleep, with topical melatonin also recommended for Retrograde Alopecia.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The user lost ground on oral finasteride and plans to switch to topical finasteride/minoxidil and microneedling. They are curious if topical treatments are more effective than oral ones.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

The user reports using topical minoxidil 6% and finasteride 0.05% once daily, along with microneedling, vitamins, biotin, and nizoral shampoo. They recently increased minoxidil and finasteride to twice daily and feel their hair is thicker but are unsure about regrowth.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user shared their 6.5-month experience with topical finasteride (2%) and minoxidil (5%), noting initial progress followed by a significant shedding phase. Others in the conversation reassured that shedding is normal and suggested staying consistent with the treatment for potential regrowth.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.

The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

The conversation discusses hair loss treatments, specifically topical finasteride and minoxidil, with users debating the effectiveness and honesty of progress pictures. Some users claim significant regrowth, while others argue about the influence of lighting and angles on perceived results.

Exosomes are being discussed as a potential hair loss treatment, with some users skeptical about their effectiveness and stability. There is interest in different types of exosomes, including those derived from centella asiatica, and comparisons are made to other treatments like finasteride.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The user experienced noticeable hairline regrowth after starting finasteride for crown hair loss, despite scalp irritation from topical minoxidil. They are impatient for crown results.

The conversation discusses using Rogaine (Minoxidil) and ketoconazole for hair regrowth, with interest in trying a formulation with Azelaic Acid for potentially better results. Concerns about Azelaic Acid's effectiveness and safety, including skin sensitivity to sunburn, are mentioned.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.